About a thousand representatives of Cuba and 50 other countries will be acquainted with Cuba’s biopharmaceutical projects, which total over a 100 and almost a third of which are vaccines.

The director of Science and Innovation of the Biocubafarma business group, Rolando Perez, made statements to the press saying that 63 percent of the projects are associated with branches of oncology, neurology and immunology. Also, of all the products in development, 20 are potentially the first of their kind.

During the event there will also be a lecture on the benefits of the application of the Cimavax vaccine against cancer and the clinical trial being conducted jointly between Cuba and the United States to treat chronic obstructive pulmonary disease therapeutically.

In accordance with Perez’s revelations, new commercial agreements are expected to be signed during Biohabana, as well as the promotion of scientific relations, given the potential of many of the continent’s territories in the field of medicine and biotechnology.

Two Nobel laureates in medicine will attend the meeting, which will last until next Friday: the American immunologist James P. Allison and the British biochemist Richard John Roberts.

The organizers also disclosed that the event will host more than 230 face-to-face conferences and a similar number in virtual format on Covid-19, medical technology and Industry 4.0, as well as chronic inflammation, cancer and autoimmunity, agricultural biotechnology and diseases of the brain.

pgh/llp/jf/ifs